MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson’s disease in a marmoset monkey model

    I. Philippens, C. Ahlem, C. Reading (Antwerp, Belgium)

    Objective: To demonstrate the effects of an oral, anti-inflammatory agent, NE3107, on motor activity, levodopa-induced dyskinesia (LID) induction, and neuron survival in a marmoset model…
  • 2023 International Congress

    Clinical progression in males and females with early treatment-naive Parkinson’s disease

    T. Kassuba, B. Ribba, T. Simuni, K. Marek, A. Siderowf, L. Chahine, M. Picillo, P. Brundin, G. Pagano (Basel, Switzerland)

    Objective: To investigate differences in the progression of motor and non-motor symptoms and striatal degeneration between males and females with Parkinson’s disease (PD). Background: Biological…
  • 2023 International Congress

    STRAT-PARK: a biomarker and stratification initiative for Parkinson’s disease

    K. Stige, S. Kverneng, S. Sharma, GO. Skeie, E. Sheard, M. Søgnen, S. Af Geijerstam, T. Vetås, C. Dölle, F. Dick, A. Wahlvåg, E. Berntsen, F. Riemer, P. Goa, K. Haugarvoll, S. Buch, D. Reese, D. Babiker, Y. Mahdi, T. Wade, G. Miranda, J. Ganguly, Y. Tamilselvam, J. Chai, S. Bansal, D. Aur, M. Haacke, M. Jog, C. Tzoulis (Trondheim, Norway)

    Objective: The STRAT-PARK initiative aims to stratify Parkinson’s disease (PD) according to underlying molecular mechanisms, and to develop clinically applicable biomarkers for patient stratification. Background:…
  • 2023 International Congress

    Navigating Open Science in Canada with the Canadian Open Parkinson Network

    M. Cressatti, C. Normandeau, C. Degroot, I. Kathol, A. Stoessl, M. Mckeown, J. Miyasaki, R. Camicioli, D. Grimes, L. Kalia, A. Strafella, P. Macdonald, N. Dupré, E. Fon, O. Monchi (Calgary, Canada)

    Objective: The Canadian Open Parkinson Network (C-OPN) is a pan-Canadian initiative that bridges people, data and resources to accelerate new discoveries in the field of…
  • 2023 International Congress

    Comparison of original and revised versions of the University of Pennsylvania Smell Identification Test

    M. Brumm, K. Pierz, W. Aamodt, C. Gochanour, R. Kurth, C. Coffey, T. Foroud, E. Brown, R. Doty, T. Simuni, C. Tanner, K. Marek, A. Siderowf (Iowa City, USA)

    Objective: To assess agreement between the original and revised versions of the University of Pennsylvania Smell Identification Test (UPSIT). Background: Recently published age/sex-specific UPSIT percentiles,…
  • 2023 International Congress

    Modeling Parkinson’s disease progression accounting for the effect of symptomatic treatments in the Parkinson’s Progression Markers Initiative study

    B. Ribba, T. Simuni, K. Marek, A. Siderowf, L. Chahine, C. Diack, A. Monnet, B. Ricci, T. Nikolcheva, G. Pagano (Basel, Switzerland)

    Objective: To explore the natural history of Parkinson’s disease (PD) accounting for the effect of symptomatic treatments on progression by modeling the time course of…
  • 2023 International Congress

    Preliminary results of the validation study of the Shame in Parkinson’s disease (SPARK) Scale

    I. Debove, C. Rodriguez-Blazquez, S. Murcia, A. Zenger, MM. Kurtis, E. Cubo, C. Falup-Pecurariu, KR. Chaudhuri, H. Reichman, S. Bostantjopoulou, M. Bereau, V. Fleury, P. Krack (Bern, Switzerland)

    Objective: The goal of this study is to validate the Shame in PARKinson’s disease (SPARK) Scale [1] which identifies the presence, the extent and some…
  • 2023 International Congress

    Artificial intelligence for the improvement of imaging biomarkers in Parkinson’s disease

    V. Dzialas, E. Doering, K. Simonyan, A. Strafella, D. Vaillancourt, T. van Eimeren (Cologne, Germany)

    Objective: To systematically review the current literature on the application of artificial intelligence (AI) for imaging biomarkers in Parkinson's disease (PD) and to identify translational…
  • 2023 International Congress

    Estimating the Incidence of Parkinson’s Disease in Patients with Epilepsy: A Nationwide Cohort Study in South Korea

    YS. Hwang, MG. Kang, MG. Lee, SW. Yeom, BS. Shin, JS. Kim, HG. Kang (Jeonju-si, Jeonbuk-do, Republic of Korea)

    Objective: We aimed to estimate the incidence of PD in patients with epilepsy and explore the association between epilepsy and PD. Background: Although epilepsy is…
  • 2023 International Congress

    Effect of Sex on the association between GBA mutations and Cognitive Decline in Parkinson’s Disease

    SP. Caminiti, M. Avenali, M. Inglese, C. Tassorelli, D. Perani (Pavia, Italy)

    Objective: To assess the impact of sex and glucocerebrosidase (GBA) mutations on cognitive trajectories in a sample of Parkinson's disease (PD) patients. Background: Accumulating evidence…
  • « Previous Page
  • 1
  • …
  • 237
  • 238
  • 239
  • 240
  • 241
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley